ACE2 and COVID-19: Human recombinant soluble ACE2 (hrsACE2) theoretically should be of benefit in COVID-19 by binding S protein and thereby neutralizing SARS-CoV-2 and by minimizing injury to multiple organs because of renin–angiotensin system hyperactivation and increased angiotensin II concentrations.